Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study

Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Maehara Y, Oki E, Saltz LB, Douillard JY, Punt CJ, Koopman M, Van[...]

Fuchs SP, Mondragon PG, Zabizhin R, Tomer S, Wang L, Cook E, Dudley DM, Weisgrau KL, Furlott J, Coonen J, Alexander E, Xie J, Gao[...]

Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on[...]